Orion Oyj (0M2N.L)

33,55 +0,05 (+0,15 %) À partir de 05:10PM BST. Marché ouvert.

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Secteur(s): 
Secteur d’activité: 
Employés à temps plein: 3 632

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Liisa Hurme	President, CEO & Chairman of Executive Management Board	770,28k	S.O.	1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)	CFO & Member of the Executive Management Board	S.O.	S.O.	1961
Mr. Olli Huotari Ll.M.	Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board	S.O.	S.O.	1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	S.O.	S.O.	1966
Prof. Outi Vaarala M.D., Ph.D.	Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board	S.O.	S.O.	1962
Mr. Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	S.O.	S.O.	S.O.
Mr. Niclas Lindstedt EMBA, M.Sc.	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	S.O.	S.O.	S.O.
Mr. Hao Pan M.Sc.	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	S.O.	S.O.	1971
Ms. Julia Irene Macharey	Senior Vice President of People & Culture and Member of Management Board	S.O.	S.O.	1977
Mr. Rene Lindell M.Sc., Ph.D.	Member of Group Executive Management Board	S.O.	S.O.	1976

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Orion Oyj en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 3; Société : 1; Droits des actionnaires : 10; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.